Full-Time

Compliance Business Partner

Research & Development & Pain, Associate Director

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$166.5k - $249.8k/yr

+ Annual Bonus + Annual Equity Awards

Senior

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid role allows for remote work up to two days per week.

Category
Legal
Risk & Compliance
Legal & Compliance
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • 5-7 years post-JD experience providing legal counsel in the biotechnology/pharmaceutical industry, including both in-house at a global biotechnology or pharmaceutical company (strongly preferred) or a combination of law firm and in-house experience.
  • Outstanding ability to effectively communicate sound advice to lawyers and non-lawyers alike, coupled with a strong understanding of business needs.
  • Expert knowledge of statutes, regulations, and guidance documents applicable to commercial, development and medical affairs activities, including research and interpretation of the Food, Drug, and Cosmetic Act; FDA regulations and guidance; federal and state anti-kickback statutes; OIG guidance documents and advisory opinions; the False Claims Act; and the PhRMA Code and extensive experience providing legal counsel on these topics.
  • Demonstrated commitment to Compliance, ethics, and accountability.
  • Flexibility to work in a fast paced and dynamic work environment with a strong work ethic and positive attitude.
  • Ability to travel on an as-needed basis.
  • Proficiency in MS Office (especially PowerPoint, Word, and Excel).
  • Law degree and legal experience required.
Responsibilities
  • Advise Global and North America business colleagues in Research & Clinical Development and the US Pain Business Unit on various initiatives in a way that advances the company’s strategy while addressing legal and compliance risks and protecting the company’s integrity and reputation.
  • Serve as the Compliance representative on leadership and cross-functional teams, providing strategic and tactical guidance and advice on projects and initiatives to drive fact- and risk-based decision making.
  • Collaborate with the OBIE Training and Communications team on substantive trainings and regular communications on Compliance policies, procedures, and areas of risk.
  • Maintain a high level of knowledge of current and emerging laws, regulations, codes, and recent enforcement actions across the US and inform and educate business colleagues with tailored communications.
  • Help to establish standards and implement procedures to ensure the Compliance Program is effective and efficient.
  • Develop and maintain strong relationships and collaborate frequently with Legal, Human Resources, Internal Audit, and colleagues in other functional areas both in and outside of the US.
  • Support continuous improvement of the Global Compliance Program.
Desired Qualifications
  • Consummate team player with excellent judgment and interpersonal skills.
  • Ability to communicate, present, and train effectively with all levels of management and employees.
  • Demonstrated experience taking ownership of issues and providing timely, practical, and actionable guidance.
  • Strong oral and written communication and influencing skills and the ability to collaborate cross-functionally proactively and pragmatically.
  • Strong analytical, organizational, and problem-solving skills.
  • Excellent project management skills with the ability to manage multiple priorities simultaneously.
  • Self-starter with demonstrated leadership skills and ability to meet goals; able to exercise sound judgment in balancing risks in ambiguous and complex situations and escalating matters appropriately.
  • Demonstrated superior ability to identify areas for improvement in controls, systems, and processes and implement effective solutions.
  • Ability to work with large amounts of data to analyze information while still seeing the “big picture.”
  • Confidence and professionalism to handle difficult conversations and discretion on sensitive matters.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).